DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Sweden
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
GENO logo

Genovis AB (publ.) Stock Price

OM:GENO Community·SEK 1.4b Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 8 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

GENO Share Price Performance

SEK 20.95
-2.40 (-10.28%)
​
SEK 20.95
-2.40 (-10.28%)
​
Price SEK 20.95
Fri, 11 Sep 26
Share Pricen/a

GENO Community Narratives

There are no narratives available yet.
Create Narrative
There are no community narratives available.

Trending Discussion

No trending discussion available.

Recently Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with high growth potential.

1 Risk
1 Reward
View Full Analysis

Genovis AB (publ.) Key Details

SEK 137.0m

Revenue

SEK 15.4m

Cost of Revenue

SEK 121.5m

Gross Profit

SEK 101.0m

Other Expenses

SEK 20.5m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Nov 10, 2026
0.30
88.73%
14.96%
0%
View Full Analysis

About GENO

Founded
1999
Employees
42
CEO
Fredrik Olsson
WebsiteView website
www.genovis.com

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOUS (SpeB), a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease. It also offers GlySERIAS, an enzyme that digests flexible glycine-rich fusion protein linkers; GlyCLICK, a conjugation technology; TransGLYCIT, a platform technology; and GingisREX, a protease that digests proteins C-terminally of arginine residues. In addition, the company offers OmniGLYZOR, a mixture of immobilized enzymes; PNGase F, a glycoamidase; OpeRATOR, an O-glycan-specific protease; ImpaRATOR, an O-glycan-dependent protease; OglyZOR, an endoglycosidase; SialEXO, a sialidase product; FucosEXO, a mix of a-Fucosidases; GalactEXO, a ß-Galactosidase mix; GalNAcEXO, an a-N-Acetylgalactosaminidase; and GlycOCATCH, an affinity resin. Further, it provides GlycINATOR (EndoS2), an IgG-specific endoglycosidase; IgGZERO (EndoS), an IgG-specific endoglycosidase; Anti-FabRICATOR (Anti-IdeS), a family of antibody products; and Anti-FabRICATOR Z (Anti-IdeZ), a goat polyclonal antibody, as well as SEQURNA RNase Inhibitor Thermostable. Additionally, the company offers antibodies, proteins, antigens, kits, and cell culture products; bioprocess and gene therapy services; and services, such as SmartEnzymes fragmentation and conjugation, antibody LC-MS analysis, and customized antibody services. It serves biotech and pharmaceutical, contract research, and contract manufacturing companies. The company was founded in 1999 and is headquartered in Kävlinge, Sweden.

Recent GENO News & Updates

Analysis Article • Jul 31

Some May Be Optimistic About Genovis AB (publ.)'s (STO:GENO) Earnings

The market for Genovis AB (publ.)'s ( STO:GENO ) shares didn't move much after it posted weak earnings recently. We...
Analysis Article • Jul 27

Earnings Miss: Genovis AB (publ.) Missed EPS By 78% And Analysts Are Revising Their Forecasts

Genovis AB (publ.) ( STO:GENO ) missed earnings with its latest quarterly results, disappointing overly-optimistic...

Recent updates

No updates

Genovis AB (publ.) Competitors

CAMX logo

Camurus

Symbol: OM:CAMX
Market cap: SEK 35.1b
BIOA B logo

BioArctic

Symbol: OM:BIOA B
Market cap: SEK 29.0b
ALIF B logo

AddLife

Symbol: OM:ALIF B
Market cap: SEK 18.7b
BONEX logo

Bonesupport Holding

Symbol: OM:BONEX
Market cap: SEK 14.8b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide